<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Highly purified human lymphoblastoid interferon (HLBI) derived from virus-stimulated Namalwa cells was administered by 6-h IV infusion or IM injection to 40 patients with a variety of <z:e sem="disease" ids="C0346957" disease_type="Neoplastic Process" abbrv="">disseminated malignancies</z:e> refractory to standard therapy </plain></SENT>
<SENT sid="1" pm="."><plain>Each patient received doses escalating from 0.1 to 50 X 10(6) U for up to 5 weeks </plain></SENT>
<SENT sid="2" pm="."><plain>Extensive monitoring for clinical effect, toxicity, and pharmacokinetics has revealed higher peak serum interferon levels and somewhat more pronounced systemic toxicity for the IV than for the IM route of administration </plain></SENT>
<SENT sid="3" pm="."><plain>Objective evidence of <z:mp ids='MP_0010537'>tumor regression</z:mp> was observed in two patients receiving HLBI IV </plain></SENT>
</text></document>